{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:30:59Z","timestamp":1789086659110,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"DAMMED"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Encorafenib is a BRAF inhibitor with a pharmacodynamic profile distinct from that of dabrafenib, including a longer dissociation half-life that may enable more sustained BRAF inhibition. It has been hypothesized that this could translate into superior clinical efficacy. We aimed to determine whether encorafenib plus binimetinib is superior to dabrafenib plus trametinib in terms of clinical activity and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were identified through the Danish Metastatic Melanoma Database, a national registry collecting prospective data on systemic treatments. We retrospectively retrieved baseline, treatment, and outcome data for patients with metastatic BRAF-mutant melanoma treated with encorafenib plus binimetinib or dabrafenib plus trametinib from 2017 to 2024. Both unmatched and propensity score\u2013matched analyses were conducted to mitigate potential confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 751 patients were included (422 dabrafenib plus trametinib, 329 encorafenib plus binimetinib). Baseline characteristics were balanced between groups. In the unmatched cohort, no statistically differences were observed between dabrafenib plus trametinib and encorafenib plus binimetinib in progression-free survival (PFS; median = 7.9 vs 8.0\u2009months; hazard ratio [HR] = 0.99, P =\u2009.90), overall survival (median = 15.5 vs 15.4\u2009months; HR = 0.91, P =\u2009.30), or melanoma-specific survival (median = 16.2 vs 15.7\u2009months; HR = 0.94, P\u2009=\u2009.50). Propensity score\u2013matched analyses confirmed these findings (PFS: HR = 1.05, P\u2009=\u2009.60; overall survival: HR = 0.922, P\u2009=\u2009.41; melanoma-specific survival: HR = 0.97, P =\u2009.74). Post hoc power analysis for detecting a 3-month survival difference was adequate for PFS (97.5%) but limited for overall survival (56.3%) and melanoma-specific survival (52.1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found no evidence that encorafenib plus binimetinib is superior to dabrafenib plus trametinib in metastatic melanoma. These findings suggest that the choice between these combinations should be guided by tolerability profiles and economic considerations rather than efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf263","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:32:54Z","timestamp":1757417574000},"page":"261-268","source":"Crossref","is-referenced-by-count":2,"title":["Dabrafenib plus trametinib vs encorafenib plus binimetinib in\n                    <i>BRAF<\/i>\n                    -mutant metastatic melanoma: a real-world propensity score\u2013matched survival analysis"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7816-3294","authenticated-orcid":false,"given":"Yago","family":"Garitaonaindia","sequence":"first","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital , Herlev 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawez","family":"Khan","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital , Herlev 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-146X","authenticated-orcid":false,"given":"Rasmus","family":"Friis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aarhus University Hospital , Aarhus 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-4335","authenticated-orcid":false,"given":"S\u00f8ren","family":"Kj\u00e6r","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital , Odense 5000,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-9281","authenticated-orcid":false,"given":"Troels H","family":"Borch","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital , Herlev 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina","family":"Ruhlmann","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital , Odense 5000,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M","family":"Guldbrandt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aarhus University Hospital , Aarhus 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A","family":"Luczak","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aalborg University Hospital , Aalborg 9000,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-3561","authenticated-orcid":false,"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aarhus University Hospital , Aarhus 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital , Odense 5000,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital , Herlev 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"Marco","family":"Donia","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital , Herlev 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-9232","authenticated-orcid":false,"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital , Herlev 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"2026021016065694900_djaf263-B1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/J.CELL.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"2026021016065694900_djaf263-B2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"2026021016065694900_djaf263-B3","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation\u2013positive advanced melanoma: extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026021016065694900_djaf263-B4","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026021016065694900_djaf263-B5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMOA1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021016065694900_djaf263-B6","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021016065694900_djaf263-B7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"2026021016065694900_djaf263-B8","doi-asserted-by":"publisher","first-page":"115124","DOI":"10.1016\/J.EJCA.2024.115124","article-title":"An update on access to novel treatment for metastatic melanoma in Europe\u2013A 2024 survey of the European Melanoma Registry and the European Association of Dermato-Oncology","volume":"216","author":"Kandolf","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026021016065694900_djaf263-B9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol Res"},{"key":"2026021016065694900_djaf263-B10","doi-asserted-by":"publisher","first-page":"eabl6339","DOI":"10.1126\/SCIADV.ABL6339","article-title":"Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy","volume":"8","author":"Ng","year":"2022","journal-title":"Sci Adv"},{"key":"2026021016065694900_djaf263-B11","doi-asserted-by":"publisher","first-page":"30453","DOI":"10.18632\/ONCOTARGET.8351","article-title":"Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity","volume":"7","author":"Adelmann","year":"2016","journal-title":"Oncotarget"},{"key":"2026021016065694900_djaf263-B12","doi-asserted-by":"publisher","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026021016065694900_djaf263-B13","doi-asserted-by":"publisher","first-page":"112957","DOI":"10.1016\/J.EJCA.2023.112957","article-title":"Adjuvant treatment and outcome of stage III melanoma patients: results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study","volume":"191","author":"Lodde","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026021016065694900_djaf263-B14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/J.EJCA.2016.11.021","article-title":"Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026021016065694900_djaf263-B15","doi-asserted-by":"publisher","first-page":"101943","DOI":"10.1016\/J.CANEP.2021.101943","article-title":"The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients","volume":"73","author":"Ellebaek","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"2026021016065694900_djaf263-B16","doi-asserted-by":"publisher","first-page":"115402","DOI":"10.1016\/j.ejca.2025.115402","article-title":"Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1\u202f% cut-off level in melanoma","volume":"221","author":"Vestergaard","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026021016065694900_djaf263-B17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/PST.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2026021016065694900_djaf263-B18","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026021016065694900_djaf263-B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/J.EJCA.2016.12.017","article-title":"The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials","volume":"74","author":"Donia","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026021016065694900_djaf263-B20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF -mutant melanoma: the DREAMseq trial\u2014ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021016065694900_djaf263-B21","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026021016065694900_djaf263-B22","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1200\/JCO.2022.40.16_SUPPL.9516","article-title":"Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E\/K-mutant melanoma: long-term follow-up of KEYNOTE-022 parts 1, 2, and 3","volume":"40","author":"Ribas","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026021016065694900_djaf263-B23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026021016065694900_djaf263-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS12061650","article-title":"Safety of braf+mek inhibitor combinations: severe adverse event evaluation","volume":"12","author":"Meirson","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026021016065694900_djaf263-B25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14740338.2023.2189235","article-title":"Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system","volume":"22","author":"Huang","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"2026021016065694900_djaf263-B26","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J Thor Oncol"},{"key":"2026021016065694900_djaf263-B27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/S10198-023-01614-6","article-title":"Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma","volume":"25","author":"Trouiller","year":"2024","journal-title":"Eur J Health Econ"},{"key":"2026021016065694900_djaf263-B28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1177\/10600280221146878","article-title":"Economic evaluation of three BRAF + MEK inhibitors for the treatment of advanced unresectable melanoma with BRAF mutation from a US payer perspective","volume":"57","author":"Halloush","year":"2023","journal-title":"Ann Pharmacother"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf263\/64790204\/djaf263.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/2\/261\/64790204\/djaf263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/2\/261\/64790204\/djaf263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:07:03Z","timestamp":1770757623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/2\/261\/8292988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf263","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,20]]}}}